A discussion about a molecule’s role in the body can make a commercial preparation sound familiar and harmless. For an injectable product, that skips an important layer: the ingredients, sterile process, final formulation, and clinical oversight.
FDA has issued a specific warning relevant to NAD+ compounding. Understanding that alert is more useful than assuming that the words “natural,” “prescription,” or “pharmacy-made” settle every safety question.
THE USEFUL DISTINCTION
Ask about the finished preparation and its dispensing pharmacy; ingredient familiarity does not establish injectable safety.
What the FDA alert says
FDA reported that some compounders were using food-grade NAD+ from repackagers to make intravenous products. Materials intended for food are not suitable for sterile compounding without appropriate processing, because microbial contamination and endotoxins can harm patients.
The agency also described reports including severe chills, shaking, vomiting, and fatigue after NAD+ injectable drugs, with some people needing medical treatment. This does not identify every product as contaminated; it explains a real category of concern that should remain visible in the decision.
Approval and compounding are different
A compounded drug is not FDA-approved. FDA does not review each compounded product for safety, effectiveness, and quality before it is marketed. A prescription or a claim of clinician oversight does not convert that preparation into an approved medicine.
Our NAD introduction separates biological plausibility from a demonstrated clinical benefit. That distinction and the regulatory distinction both matter: neither a mechanistic story nor a provider’s confidence replaces product-specific evidence and quality controls.
Evidence: FDA: compounding and approval
Ask for practical answers
Identify the pharmacy, confirm its licensing through the appropriate authority, and ask your pharmacist about storage, shipment conditions, beyond-use information, and the instructions on the actual label. If the package or directions are unclear, obtain clarification before using it.
Do not copy a volume or schedule from an advertisement. Products can differ, and a review cannot determine your prescription. Read the injection-versus-infusion comparison for questions about who supervises care and handles problems in each setting.
Evidence: FDA: BeSafeRx / FDA: suitable ingredients for sterile compounding
A reaction deserves an appropriate response
Severe or rapidly worsening symptoms should not be dismissed as evidence that a treatment is working. Seek urgent assessment for concerning reactions, and emergency help for symptoms such as difficulty breathing, collapse, or severe chest pain. Contact the treating clinician about non-emergency adverse effects and the plan for further use.
Before enrollment, ask how that contact works and who is clinically responsible. The provider shortlist and cost guide are research aids, not a finding that a listed product is safe or suitable for an individual.
Evidence: FDA: suitable ingredients for sterile compounding / CoreAge Rx: NAD+ injectable product page / AgelessRx: NAD+ injections
Open the source material
- FDA: suitable ingredients for sterile compounding
Specific NAD+ safety communication: food-grade material, contamination risk and reported adverse events.
- FDA: compounding and approval
Compounded drugs are not FDA-approved; ingredient evidence does not certify the finished preparation.
- FDA: BeSafeRx
Online pharmacy checks, not certification of a particular brand.
- CoreAge Rx: NAD+ injectable product page
Commercial description and starting price checked September 23, 2026. Benefit claims are not independent efficacy evidence.
- AgelessRx: NAD+ injections
Advertised $79 first month on a three-month plan billed in full, then $149 per month. Confirm final terms; surveys are not controlled trials.
